Abstract
Injectable polyacrylamide hydrogel (PAAG) is a jelly-like transparent implant used in breast augmentations. This type of implant had been used since 1998, but its use was prohibited in China in 2006 due to numerous complications that had arisen from its use. In one case, a rare appearance of PAAG tissue degeneration was observed 7 years after an injectable breast augmentation using PAAG.
References
Cheng N-X, Wang Y-L, Wang J-H et al (2002) Complications of breast augmentation with injected hydrophilic polyacrylamide gel. Aesthetic Plast Surg 26:375–382
Besaratinia A, Pfeifer GP (2003) Weak yet distinct mutagenicity of acrylamide in cells. J Natl Cancer Inst 95:889–896
Janneke GH, Leo JS, Erik JK, Goldbohm RA, Brandt PA (2008) Dietary acrylamide intake and the risk of renal cell, bladder, and prostate cancer. Am J Clin Nutr 87:1428–1438
Takafumi Y, Masao H, Shinsuke Y, Yoshimasa O et al (2001) Evaluation of acrylamide and 3,3’-iminodipropionitrile-induced neurotoxicity in a rat 28-day oral toxicity study: collaborative project for standardization of test procedures and evaluation of neurotoxicity. J Toxicol Pathol 14:279–287
Wang H, Huang P, Lie T, Li J, Hutz RJ, Li K, Shi F (2010) Reproductive toxicity of acrylamide-treated male rats. Reprod Toxicol 29:225–230
Xiao ZB (2008) The relationship between breast cancer and breast augmentation with injected polyacrylamide gel: two case reports. J Plast Reconstr Aesthet Surg 61:981–982
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Xu, C., Cao, M., Bao, B. et al. Tissue Degeneration 7 Years After Breast Augmentation With Injected Polyacrylamide Hydrogel (PAAG). Aesth Plast Surg 36, 160–162 (2012). https://doi.org/10.1007/s00266-011-9779-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00266-011-9779-8